香港, 2026年4月2日 - (亞太商訊 via SeaPRwire.com) - 國元國際4月1日發表更新研究報告表示，億勝生物科技（1061.HK）2025年業績穩健增長，實現營業收入18.14億港元，同比增長8.6%，主因眼科與外科板塊持續發力。國際化序幕拉開，貝伐珠單抗三期臨床試驗達到主要臨床終點，貝複舒(R)已進入新加坡市場，隨著創新藥未來全球商業化順利推進，將推動公司業績上升。國元國際重申對億勝生物買入「評級」，目標價6.84港元。公司核心研發管線迎來多項關鍵里程碑，抗VEGF眼內注射液EB12-20145P（HLX04-O，貝伐珠單抗）的上市註冊申請已獲中國國家藥品監督管理局藥品審評中心受理，其全球多中心三期臨床試驗（AURA2）已完成最後一名患者的最後一次訪視（FDA, EMA, TGA），目前處於數據統計中。該產品中國三期臨床研究顯示，其在第 48 周最佳矯正視力（BCVA）較基線改善的平均字母數變化上非劣於雷珠單抗，達到主要研究終點，安全性表現良好，目前全球上市貝伐珠單抗產品均無濕性AMD適應症，市場挖掘空間廣闊。同時公司從Mitotech獲得全球獨家權益的SkQ1滴眼液正推進美國三期臨床試驗，產品具備優秀的安全性和耐受性，對標規模龐大的中國中度至重度乾眼症患者市場，潛力巨大。公司國際化戰略取得標誌性成果，貝復舒(R)已通過新加坡特別採用程序（SAR）成功引入新加坡國家眼科中心（SNEC），標誌產品首次進入中國以外地區，為未來在東南亞及全球市場推出奠定基礎；同時公司已與北京鷹瞳科技發展股份有限公司訂立合作共同經營基於人工智能的視網膜業務，並與浙江視方極醫藥科技有限公司就富馬酸依美斯汀及鹽酸奧布卡因滴眼液訂立獨家分銷協議，持續完善眼科產品矩陣與業務佈局。國元國際指出，隨着貝伐珠單抗三期臨床試驗達到主要臨床終點、貝復舒(R)成功進入新加坡市場，未來公司創新藥全球商業化的順利推進，將持續帶動公司業績穩步上升。基於公司穩健的經營基本面、核心研發管線的突破性進展及國際化發展的廣闊空間，國元國際維持公司目標價格6.84港元，對應2025年PE為12倍，較現價有84.9% 的上漲空間，維持「買入」評級。重要披露：本文引用國元國際控股有限公司於2026年4月1日發表的研究報告內容。本資料僅供參考，不構成投資建議，投資有風險，請謹慎決策。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月2日 - (亞太商訊 via SeaPRwire.com) - 據阿思達克財經網報道，近期，聯想控股（3396.HK）發佈亮眼業績，2025年公司實現收入與淨利潤雙增長，其中最引起筆者注意的是在報告期內成功推動15家被投企業上市，名列市場前茅。自2025年底以來，香港資本市場氣氛顯著回暖，港股IPO呈現活躍態勢，以人工智能、生物醫藥、先進製造為代表的硬科技企業上市進程明顯加速。在此輪科技股上市浪潮中，聯想控股（3396.HK）憑藉其前瞻佈局，迎來了旗下被投企業的密集資本化，成功推動多家細分領域龍頭登陸港交所，不僅精準把握了市場窗口，更印證了其科創戰略佈局正步入收穫階段，為公司整體的價值重估與戰略聚焦提供了有力支撐。IPO密集落地 科創佈局進入收穫期而這一勢頭在進入到2026年後也絲毫沒有減弱。年初至今，聯控體系內又有多家企業完成港股IPO，這一批IPO的集中落地，不僅是投資回報的兌現，更折射出聯想控股在科技領域的「提前量」。以具身智能為例，該賽道在今年政府工作報告中被正式納入國家戰略，成為重點培育的未來產業。而聯控體系在該領域的被投企業已近50家，數量行業領先、門類最為完整。其中，聯控旗下聯想之星作為早期投資先鋒，在2026年初表現尤為突出：精鋒醫療（手術機器人）、瑞博生物（小核酸藥物）、愛芯元智（邊緣AI芯片）先後成功上市，分別填補或引領了各自細分領域「港股第一股」的空白。這三家企業均是所在賽道的技術領軍者，其上市即受到市場關注，凸顯了聯想之星在硬科技早期投資中的精準洞察力。與此同時，聯控旗下君聯資本亦成果豐碩，其長期陪伴的產業級AI智能體企業海致科技於2026年2月成功登陸港交所，上文提到的精鋒醫療與瑞博生物背後也有君聯一路支持的身影。而此前已於2025年上市的「大模型第一股」智譜，同樣是聯想控股體系內（通過君聯資本、聯想創投等）進行多輪投資與生態賦能的案例。這些佈局集中覆蓋了當前國家戰略重點支持、資本市場高度青睞的人工智能、生物科技及高端醫療器械等前沿方向，標誌著聯想控股構建的科技投資生態已進入成果批量湧現期。退出回籠資金 戰略聚焦再添彈藥對於投資控股型公司而言，退出能力與投資能力同等重要。過去幾年，資本市場波動一度讓退出成為行業難題，但2025年港股IPO回暖，為聯想控股提供了難得的退出窗口，得以回籠資金，公司全年通過各種方式共計回流現金74億元，而據統計聯控在「十四五」期間累計回流的資金則超過450億元。與此同時，這些回籠資金被重新投入到科技創新主業中。過去五年，聯想控股在科技研發上投入超750億元，較「十三五」期間增長超60%；而聯控體系保持平均每年新投資和追加投資超100家科技企業的節奏，其中覆蓋AI、具身智能、商業航天、低空經濟、新能源新材料、可控核聚變、芯片半導體、量子計算、生物醫藥等多個國家新興支柱產業和未來產業。尤其在人工智能領域，聯控可以說是中國在該領域投資時間最長，覆蓋最全面的機構，累計投資AI企業超過300家。這種「投資—培育—退出—再投入」的良性循環，讓聯想控股在外部環境波動中始終保持著戰略定力。當前，聯想控股手中既握有已上市及儲備中的科技領軍企業清單，也具備了通過資本循環持續優化資產、聚焦科技主業的清晰路徑與執行能力。在「十五五」強調科技自立自強的宏觀背景下，隨著其中長期投資價值的持續釋放以及戰略轉型意圖的有效落地，該公司獨特的孵化培育能力與科創引領發展的佈局成效，已成為其價值重構的堅實支點，有望在後續資本化進程中持續兌現。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Luxury new energy vehicle (NEV) enterprise Seres officially released its 2025 annual results on March 30, with several core financial indicators recording steady growth and profitability continuing to strengthen for the second consecutive year, attracting widespread market attention.The results report shows that in 2025, Seres achieved revenue of approximately RMB164.89 billion with a year-on-year increase of 13.63%, net profit attributable to shareholders of the listed company was RMB5.96 billion and R&D investment reached RMB12.51 billion, a year-on-year increase of 77.4%. The Company also announced a proposed final dividend of RMB0.8 per share (tax included), totaling approximately RMB1.9 billion in cash dividends, reflecting its commitment to rewarding shareholders.In terms of sales performance, Seres' NEV sales continued to maintain a high level. Annual sales in 2025 reached 472,269 units, representing a year-on-year increase of 10.63%. The Group's premium brand AITO recorded cumulative annual deliveries exceeding 420,000 units, making it the best-selling Chinese luxury automotive brand in the domestic market. Across the full lineup, the AITO M5, M7, M8, and M9 collectively surpassed one million cumulative deliveries. The coordinated growth in both sales and profit further strengthened the Group's overall operational resilience and risk management capabilities.In terms of R&D investment, Seres has maintained a strong commitment. In 2025, the Company’s R&D investment reached RMB12.51 billion, representing a year-on-year increase of 77.4%. Both the intensity and growth rate of R&D investment remained industry-leading, reflecting the Company’s adherence to a technology-driven strategy and laying a solid foundation for future product iteration and core competitiveness.The Group’s cash flow performance was also robust. As of December 31, 2025, net cash flow from operating activities amounted to RMB28.12 billion. Ample cash reserves enabled the Company to support high-intensity R&D and international expansion while building a stronger risk buffer and enhancing strategic flexibility.Kaiyuan Securities, Changjiang Securities, CICC, and Guotai Haitong are among the major brokerages maintaining positive ratings on Seres — Kaiyuan and Changjiang with "Buy," Guotai Haitong with "Overweight," and CICC with "Outperform" alongside a revised target price of RMB 120. All institutions are optimistic on Seres' long-term growth prospects, noting that underlying business fundamentals continue to improve with a clear and compelling growth thesis. Key catalysts include a dense Q2 model launch cycle (AITO M6 and refreshed M9/M8), accelerating overseas expansion into the Middle East and Europe, and a robotics business increasingly seen as a credible second growth curve.Overall, Seres delivered a comprehensive upgrade in its 2025 results, spanning sales volume, profit, R&D and cash flow. The Company stated that it will continue to position itself as a luxury vehicle enterprise, deepen its presence in the intelligent NEV sector, further increase investment in core technologies, enrich its high-end product portfolio, accelerate its global market expansion, and focus on improving profitability and core competitiveness, thereby supporting the continued upgrading of China’s new energy vehicle industry. For investors, this performance has undoubtedly strengthened confidence in the Company’s future growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector’s future.A clear signal of the company’s growth arrived in February 2026, when HighTide Therapeutics (2511.HK) announced a high-profile executive appointment: Dr. Filip Surmont joined the company as Chief Medical Officer (CMO).For professionals in the cardiovascular, renal, and metabolic fields, this is a name that carries real weight. Over a career spanning three decades, Dr. Surmont has held senior medical leadership roles at multinational giants including Wyeth, Pfizer, and AstraZeneca. Among his most notable contributions was his role in the global strategic development of the SGLT-2 inhibitor dapagliflozin — a landmark effort that required close collaboration across functions and geographies within a large multinational organization. As part of a talented cross-functional team, he helped shape the strategy that positioned dapagliflozin as a global metabolic blockbuster, ultimately reaching $8.405 billion USD in sales in 2025.Notably, just a few months earlier, HighTide Therapeutics' core product, HTD1801, had outperformed dapagliflozin across multiple key cardiovascular, renal, and metabolic endpoints in a head-to-head Phase III clinical trial for type 2 diabetes mellitus (T2DM).For Dr. Surmont, transitioning from managing a reigning "blockbuster" to joining a “challenger” Chinese biotech was far from coincidental. What drew him out of his comfort zone was not just HTD1801's strong glucose-lowering performance, but also the breakthrough potential this new molecular entity (NME) has shown in cardiovascular, kidney and metabolic (CKM) disease in general, and chronic kidney disease (CKD) more specifically — driven by a fundamentally differentiated pathophysiological mechanisms.I.Challenging Clinical Complacency in CKD: The Quest for True ReversalWithin the medical community, chronic kidney disease (CKD) has long been a source of frustration. Once the kidney function begins to decline, it typically deteriorates progressively and irreversibly over time, leaving most patients facing dialysis or kidney transplantation as an eventual outcome."There has long been a degree of complacency in CKD treatment among physicians, patients, and even caregivers," Dr. Surmont noted pointedly. "A mindset has taken hold that the progressive decline in renal function with age is inevitable. I’ve been striving to change this mindset throughout my career, both during my time at multinational pharmaceutical companies and now."Current standard treatments — including ACE inhibitors/ARBs and the widely used SGLT-2 inhibitors — have demonstrated efficacy in slowing disease progression, yet fall short of halting or reversing the underlying pathology. They can significantly reduce the rate of decline in the estimated glomerular filtration rate (eGFR), buying patients valuable time, but fail to alter the terminal trajectory towards kidney failure.Further complicating the clinical picture is the multi-factorial nature of CKD. Taking diabetic kidney disease (DKD) caused by T2DM as an example, besides pathophysiological factors driven by metabolic dysfunction, it is complicated by interconnected and highly complex factors such as hemodynamic perturbances, chronic inflammation, fibrosis, and other non-diabetic factors that fuel each other to worsen disease prognosis.Existing standard-of-care drugs often address only one dimension of the disease by regulating hemodynamics or a single metabolic pathway, making it difficult to comprehensively address the inflammatory damage in the renal microenvironment.II.Inside the Mechanism: Remodeling Renal Architecture via a Dual Metabolic and Anti-inflammatory PathwayThe emergence of HTD1801 provides a new key to breaking this deadlock.As an oral anti-inflammatory and metabolic modulator (AIMM) independently developed by HighTide Therapeutics, HTD1801 demonstrates a unique therapeutic potential at the microscopic level as compared to traditional drugs. Rather than relying on a single mechanism, it takes a "two-pronged" approach by activating AMPK (adenosine monophosphate-activated protein kinase) and inhibiting the NLRP3 inflammasome.Dr. Surmont has full confidence in the scientific logic underpinning this mechanism: "This drug acts simultaneously on two critical levels: beyond blood sugar, it improves overall metabolic efficiency at its source; at the same time, it directly suppresses the underlying chronic inflammation that drives organ damage."Taking a deep dive into its mechanism of action, HTD1801's dual mechanism precisely targets multiple microstructures within the kidney. "This is reflected across different renal compartments," Dr. Surmont explained. "From the filtering glomeruli and the structural interstitium to the reabsorptive tubules, and even podocytes—the vital gatekeepers of the filtration barrier, the dual action of AMPK activation and NLRP3 inhibition has demonstrated stronger-than-expected protective benefits."This mechanistic rationale, spanning from metabolic regulation to organ-level protection, has ultimately been validated by clinical data.At the 2025 American Society of Nephrology (ASN) Annual Meeting, HighTide Therapeutics presented as a late breaker Phase III clinical study data in T2DM patients with mild renal impairment. The results captured the industry's attention: compared with the placebo group, the HTD1801 group demonstrated a significant and sustainable difference in annualized eGFR slope of +9.81 ml/min/1.73 m²/year.In the eyes of nephrologists, a "positive slope" on the eGFR curve is a strong and unique signal, suggesting the possibility of early structural recovery."What we need to do next is confirm that this eGFR repair effect observed in DKD also holds true for CKD patients not driven by diabetes," Dr. Surmont revealed, indicating that relevant clinical studies are already underway, with more detailed data expected to validate this cross-etiology therapeutic potential.III.From "Rescue" to "Prevention": Advancing a Holistic Cardiorenal Metabolic (CKM) MindsetDr. Surmont brings to HighTide Therapeutics more than just clinical expertise; he brings a “game-changing” mentality that transcends a single-drug perspective.Another career-defining milestone for Dr. Surmont was his leadership role in helping reshape global asthma treatment guidelines. Historically, asthma management relied on short-acting bronchodilators for "rescue" only upon exacerbation of symptoms and shortness of breath. Dr. Surmont proposed and validated the "Anti-Inflammatory Reliever (AIR)" strategy a modern asthma management strategy that uses a combination inhaled corticosteroids and a bronchodilator as a reliever — treating both the acute bronchospasm and the underlying airway inflammation with every dose, in contrast to traditional short acting dilator-only relief. This shift ultimately benefited approximately 120 million patients worldwide and reshaped treatment paradigms.Now, facing CKD, he sees the same opportunity for a paradigm-shifting breakthrough.Given HTD1801's strong potential to repair mild renal impairment, future clinical guidelines could reasonably recommend initiating treatments early, when eGFR is still at a relatively high level. By establishing a positive trajectory for renal function recovery early in the disease, there is hope that most patients can completely avoid the looming threat of dialysis.From a health-economics perspective, this would reallocate healthcare spending: shifting funds away from costly late-stage interventions (such as dialysis and heart failure rescue) towards highly cost-effective early treatment, thereby generating substantial healthcare cost savings for society and reducing patients’ financial burden for late-stage interventions.Dr. Surmont also strongly advocates for a holistic management approach to "Cardiovascular-Kidney-Metabolic (CKM)" health. As multifunctional drugs like HTD1801 continue to evolve, he believes physicians will move beyond the single-dimensional therapeutic mindset."My ideal scenario is that all physicians managing cardiovascular, metabolic, renal, hepatic, or even obesity issues would evaluate the patient with a holistic mindset," he says, pointing to the current siloed nature in clinical practice. " As an example eGFR monitoring is not always part of routine cardiological assessment, yet at the mechanistic level, cardiac and renal dysfunction are manifestations of the same underlying disease process — making an integrated view essential"He cited a successful experiment he led while promoting dapagliflozin in China: requiring cardiologists at partner hospitals to measure patients' eGFR during their consultations. By merely adding this simple cross-disciplinary action, the number of patients on guideline directed medical treatment tripled within six months.IV.A Buyer's Lens: The Booming BD Activity in CKD and HighTide Therapeutics’ Confidence in Value CreationAs a core member of the company's leadership team, Dr. Surmont also frequently examines HighTide Therapeutics' position through the lens of capital market and industry dynamics.Over the past two years, the global biopharmaceutical market has seen a surge in business development (BD) activity in the CKD field. In 2025, Roche announced a major collaboration with Zealand Pharma valued at up to $5.3 billion; multinational giants like Novartis, Boehringer Ingelheim, and Novo Nordisk have also been making significant investments to secure premium assets in the metabolic and renal disease space.Dr. Surmont, drawing on his extensive multinational experience, has a clear read on this "land grab" phenomenon: "The core driver is the massive profit potential and rapid growth in this field. Five years ago, the therapeutic arsenal here was relatively limited. Now, with breakthrough blockbusters like GLP-1RAs and SGLT-2i’s, the kidney disease landscape has been reshaped, yet there remains a residual risk is 60–80% of the original event burden.He further elaborated: "Even when patients are treated with four pillars of therapy (ACEi/ARBs, SGLT-2i’s, GLP-1RAs, MRAs), the complex underlying inflammatory mechanisms remain largely unaddressed, still leaving a significant gap in our ability to fully protect the kidney. This creates substantial pricing potential and broad combination therapy prospects for drugs with fundamentally new mechanisms like HTD1801.""Looking back at the history of SGLT-2 inhibitors, it took over a decade from approval to reaching 20%-25% guideline-directed clinical uptake. The slow progress was partly due to a lack of strong medical education and advocacy, and partly because of physicians and patients’ tendency to yield to the disease's natural trajectory."Now, having taken the helm as CMO of HighTide Therapeutics, Dr. Filip Surmont is poised to challenge the status quo and break this complacency with solid clinical data and a new medical narrative. For this drug—born from Chinese innovation with a global ambition—the voyage in the CKM field has only just begun. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa Launches New Scheduled Flight Connecting Jakarta With Lombok, Its World Class Surfing Island DestinationJAKARTA, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - TransNusa has announced the launch of a new direct scheduled flight connecting Jakarta and Lombok, further strengthening access to one of Indonesia’s key tourism and regional travel hubs.TransNusa Airlines Group Chief Executive Officer, Datuk Bernard Francis said that the introduction of this new route comes on the back of the airline’s focus to increase and strengthen connectivity while boosting domestic tourism.“Lombok is not only rapidly growing as a domestic and international tourist destination but the island is also the main gateway for tourism in the West Nusa Tenggara region through its Lombok International Airport,” Datuk Francis said, adding that Lombok attracts more than 1.2 million tourists annually.LOMBOK… Paradise of divers and surfersLombok is home to the diving haven Gili and Mount Rinjani National Park, one of Indonesia’s most iconic volcanic landscapes. The island offers dramatic trekking routes, cascading waterfalls and panoramic mountain views, attracting adventurers and nature lovers from around the world. Beyond its mountains, Lombok has also built a global reputation as a world-class surfing and diving destination, with pristine beaches, coral reef and consistent waves drawing surfers year-round.“TransNusa will initially operate 14 flights a week or two daily flights with the first scheduled flight departing Jakarta in the morning and the second in the afternoon,” Datuk Bernard said, adding that the sales of tickets for the new scheduled flight from Jakarta to Lombok started on 16 March 2026, with the inaugural flight scheduled for April 17, 2026.DATUK BERNARD FRANCIS… Lombok is the main gateway for tourism in the West Nusa Tenggara regionIn addition to this new launch, TransNusa has also increased the frequency of its Jakarta-Yogyakarta route with the aim to enhance and strengthen domestic connectivity, said Datuk Bernard.Flight DetailsTransNusa’s scheduled flight 8B 5161 will depart Soekarno–Hatta International Airport at 5:00am and arrive at Lombok International Airport at 8:00am. The returning service, 8B 5162, will depart Lombok International Airport at 8:30am and arrive in Jakarta at the Soekarno–Hatta International Airport at 9:30am. The second scheduled flight 8B 5165 will depart Jakarta’s Soekarno–Hatta International Airport at 03:00pm and arrive at the Lombok International Airport at 05:45pm. The returning service, 8B 5166 will depart Lombok International Airport at 06.15pm and arrive at the Soekarno–Hatta International Airport at 06.45pm.Ticket prices for TransNusa’s scheduled Jakarta-Lombok route start from as low as IDR899,000, CNY390, USD55, MYR225, AUD80, and SGD69. Tickets will be available for purchase at www.transnusa.co.id and on primary online travel agents’ platforms.Meanwhile, TransNusa’s additional scheduled flight for its Jakarta-Yogyakarta flight, 8B 5530, will depart Jakarta’s Soekarno–Hatta International Airport at 10.40am and arrive at the Yogyakarta International Airport at 11.50am. The flight, 8B 5531, will depart Yogyakarta at 01.20pm and arrive in Jakarta at 02.30pm.For its flights, TransNusa not only provides premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our SEAT passengers will enjoy check-in baggage of up to 20kgs,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.For the highest package, FLEXI-PRO, we provide services such as free baggage up to 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding counters.In addition, TransNusa also provides its FLEXI-PRO passengers with the flexibility to change their flight schedule without restrictions and obtain refund when needed,” added Datuk Bernard.TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” stressed Datuk Bernard.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.About TransNusaTransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022.In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali.On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Perth, Shanghai, and Shenzhen. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia.TransNusa’s Primary International Media Contact:Trina Thomas Rajtrina@myqaseh.org+60124992672 (whatsapp only) Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings’ (0697.HK) investments in the robotics sector are moving from early-stage positioning toward value realization.Management has disclosed that, by the end of 2025, the Company—through multiple industry funds under its management—had cumulatively invested more than RMB 2 billion across the broader robotics industry chain, covering more than 20 companies. According to the Chairman’s Statement for 2025, the valuation of the investment portfolio of the Beijing Robot Industry Development Investment Fund (Limited Partnership) increased by approximately fourfold. On that basis, the corresponding unrealized book gain is estimated at around RMB 8 billion. The robotics business has therefore become one of the most closely watched sources of incremental upside for Shoucheng Holdings in the near term.Based on disclosed projects, Shoucheng Holdings’ robotics strategy is not a series of isolated bets, but rather a systematic deployment across the industry chain. In the field of embodied intelligence and robotics, the Company has made concentrated investments in more than 20 leading companies, including Unitree Robotics, Noetix Robotics, Galbot, DEEP Robotics, Booster Robotics, and Galaxea AI. In the latest Chairman’s Statement, Chairman Zhao Tianyang characterized this approach as “track-level deployment”.Unlike some purely financial investors, Shoucheng Holdings is advancing its robotics business from simply “holding equity stakes” to “operating an industry”. Following an integrated path of “investment + operations + ecosystem,” the Company is building capabilities centered on “funds + scenarios + industry chain,” providing robotics companies with capital support, application scenarios, supply-chain integration, and commercialization pathways. On the offline channel side, its robotics consumer experience brand, Taozhu New Creation, has established five stores in Beijing, with locations including Shougang Park, Beijing Capital International Airport Terminals 2 and 3, and Wangfujing APM, among other core venues. To date, the Company has signed agreements with nearly 100 robotics companies as authorized agents.Market analysts note that the valuation logic for Shoucheng Holdings’ robotics business is transitioning from book valuations in the primary market toward more observable pricing in the capital markets. As a representative investment within Shoucheng Holdings’ robotics portfolio, Unitree Robotics—together with its IPO progress—provides the market with a clearer anchor for assessing the value of Shoucheng Holdings’ robotics assets.From a longer-term perspective, the data points of “more than RMB 2 billion invested, more than 20 companies covered, and portfolio valuation increasing approximately fourfold to around RMB 8 billion” already outline the basic contours of Shoucheng Holdings’ robotics strategy:At the front end, the Company secures leading projects through its funds.In the mid-stage, it accelerates commercialization through channels and service systems.At the back end, it opens up exit and re-rating opportunities through IPOs and capital operations.As projects such as Unitree Robotics move into the capital-market spotlight, the book value of Shoucheng Holdings’ robotics investments, its industrial synergy capabilities, and its subsequent monetization path are becoming increasingly clear. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月2日 - (亞太商訊 via SeaPRwire.com) - 首程控股（0697.HK）在機器人賽道的投資，正在從前期布局轉向價值兌現。公司管理層透露，截至2025年末，公司通過管理的多支產業基金在泛機器人產業鏈累計投資金額已超過20億元，覆蓋20餘家企業。根據公司2025年主席報告書披露，其參與管理的北京機器人產業發展投資基金投資組合估值已增長約4倍，按這一口徑測算，對應賬面浮盈約80億元，機器人業務已成為首程控股近階段最受關注的增量看點。從已披露項目看，首程控股的機器人投資並非單點押注，而是沿產業鏈展開系統布局。公司在具身智能和機器人領域「集中投資了宇樹科技、松延動力、銀河通用、雲深處、加速進化、星海圖20餘家頭部公司」，公司主席趙天旸在最新發布的主席報告書中將這一打法定義為「賽道級布局」。與部分財務投資機構不同，首程控股正在把機器人業務從「持有股權」推進到「經營產業」。公司圍繞「投資+運營+生態」一體化路徑，構建「基金+場景+產業鏈」能力，為機器人企業提供資金支持、場景應用、供應鏈整合和商業化路徑打通等服務。在線下渠道端，旗下機器人消費體驗品牌「陶朱新造局」已在北京完成5家門店布局，落點包括首鋼園、首都機場T2和T3、王府井APM等核心場景；目前，公司已簽約近百家機器人公司成為授權代理商。市場分析人士指出，首程控股機器人業務的估值邏輯，正在由一級市場賬面估值向更可觀察的資本市場定價過渡。宇樹科技作為首程控股機器人投資版圖中的代表性項目，其IPO進展為市場觀察首程控股機器人資產價值提供了更清晰的錨點。放在更長週期看，「投資超20億元、覆蓋20餘家企業、投資組合估值增長約4倍至80億元」這一組數據，已經勾勒出首程控股在機器人賽道的基本輪廓：前端通過基金完成頭部項目卡位，中端通過渠道和服務體系推動商業化落地，後端借助IPO和資本運作打開退出與重估空間。隨著宇樹科技等項目進入資本市場視野，首程控股機器人投資的賬面價值、產業協同能力和後續兌現路徑，正在變得更加清晰。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PHILADELPHIA, PA AND WILMINGTON, DE, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. (NASDAQ:DVLT), an AI-driven data monetization, RWA tokenization, and Web 3.0 infrastructure company, and Demora Foundation, the Delaware-incorporated governing organization of the Demora Chain ecosystem (governed under JP3E Holdings Inc.), today announced the execution of a Technology Integration Agreement establishing Datavault AI as the formal AI data intelligence and RWA tokenization technology partner for the K-Entertainment & K-Wave Global Platform - the integrated K2Global + Demora Foundation ecosystem that converts Korean cultural IP, live entertainment, and K-Wave soft power into institutional-grade, on-chain financial products, deployed across three US Innovation K-Wave Cities: Atlanta (GA), Dallas (TX), and New York Tri-State.K-WAVE AUDIENCE SCALE200M+Global Hallyu Fans · 156 Countries$40B+K-Wave Annual Economic Impact (KOFICE 2024)$14B+K-Pop Revenue 2025E (Live + Streaming + Merch)120M+Dedicated K-Pop Concert Fans Globally500+Korean SMBs · 8 K-Wave Sectors · K2Global Mandate$3B+K-Entertainment Tokenizable Pipeline (DMR-LIVE)3US Innovation K-Wave Cities (ATL · DAL · NY Tri-State)8-14%Target DMR-LIVE Token Yield (Annualized)The Agreement deploys Datavault AI's full enterprise AI stack - Data Vault®, DataValue®, DataScore®, and Information Data Exchange® (IDE) Digital Twin - as the AI data intelligence and RWA/VWA tokenization backbone of Demora Chain, purpose-built to score, value, credentialize, and tokenize K-Entertainment assets - including K-Pop concert revenues, K-Drama IP royalties, K-content digital rights, K-Beauty brands, and K-Food franchises - as yield-bearing instruments settled in DMR (apex RWA) and GMMT (VWA layer) on Demora's dual OP Stack Layer 2.The K-Entertainment Opportunity - 200M+ Fans, $11B-$16B Annual Event Revenue, $3B+ Tokenizable PipelineThe Korean Wave (Hallyu) is the most scalable cultural export engine in the world - and the foundational demand signal for the entire DVLT × Demora Foundation partnership. With 200M+ Hallyu fans across 156 countries generating over $40B in annual economic impact, K-Entertainment represents an institutional-scale, pre-qualified audience base no other RWA protocol can access.K-Entertainment Audience & Tokenizable Pipeline - By VerticalK-Wave VerticalGlobal Fan BaseAnnual Event Revenue Est.Digital / Streaming LayerDMR-LIVE Tokenization OpportunityK-Pop Live Concerts & Tours120M+ dedicated fans$6B - $8B globallyWeverse, YouTube, streaming rights$1.5B+ addressableK-Drama & Film IP Events80M+ drama viewers$2B - $3B IP + premiere circuitNetflix, Disney+, local OTT licensing$600M+ addressableK-Food & Culinary Festivals50M+ global K-Food consumers$800M - $1.2B festivals/franchiseExport brands, franchise licensing$250M+ addressableK-Beauty Brand Events & Launches60M+ active K-Beauty consumers$1B - $1.5B experiential marketingD2C, influencer, brand collab$300M+ addressableGaming, Esports & Webtoon Festivals40M+ K-gaming & esports fans$1.2B - $2B event + IPStreaming, IP licensing, game merch$400M+ addressableTOTAL K-Entertainment TAM200M+ Hallyu Fans (composite)$11B - $16B annual event revenue$5B+ digital overlay$3B+ tokenizable pipelineDMR-LIVE Protocol - K-Entertainment RWA Tokenization EngineAt the core of the DVLT × Demora Foundation partnership is DMR-LIVE - the K-Entertainment RWA tokenization protocol that converts live event cash flows (ticket receivables, venue revenues, VIP hospitality, IP/sponsorship contracts) into yield-bearing digital assets settled on Demora Chain. Datavault AI provides the AI data intelligence layer that makes DMR-LIVE institutional-grade.DMR-LIVE - Projected Deployment & Deal ScalePhase 1 · 0-6 MonthsPilot Launch5-10 K-Wave flagship events (US + Korea)DMR-LIVE token launch on Demora Chain$25M - $50M initial pool issuance500K - 1M live attendeesInstitutional LP onboarding (Reg D)Phase 2 · 6-18 MonthsScale & Liquidity20-40 multi-genre eventsUS, Korea, Africa, SE Asia$100M - $300M issuance target3M - 8M live + digital viewersSWF / Ex-Im institutional channelPhase 3 · 18-36 MonthsGlobal Integration100+ events per annual cycleGlobal deployment (20+ countries)$300M+ annual issuance run-rate15M - 30M annual audienceNASDAQ SPAC pathway for K2GlobalDatavault AI - Powering K-Entertainment IP Intelligence & TokenizationDatavault AI's enterprise platform serves as the data intelligence layer that transforms K-Entertainment assets from illiquid cultural IP into institutional-grade, on-chain financial products:K-Pop & Content IP - IDE Digital Twin & NIL CredentialingOn-chain digital twin representations of K-Pop artist brands, K-Drama IP rights, digital content royalties, and NIL (Name, Image, Likeness) credentials - enabling programmable IP monetization and VWA issuance on GMMT layer.K-Entertainment Asset Valuation - DataScore® AI AgentsAI-based scoring and valuation of K-Pop artist tour revenue forecasts, K-Drama IP licensing streams, K-content streaming rights, and live event cash flow projections - providing the institutional-grade data oracle powering DMR-LIVE token pricing.Franchise & Brand Asset Scoring - DataValue®Comprehensive valuation scoring for K-Beauty brands, K-Food franchise systems, and K-Fashion design IP - preparing these assets for DMR-denominated RWA tokenization and cross-border distribution settlement on Demora Chain.Entertainment & Sports Vertical - HPC Software LicensingHigh-performance compute infrastructure for real-time K-Wave asset valuation, streaming rights scoring, and DMR-denominated tokenization at institutional scale - spanning K-Pop, K-Drama, K-Gaming, and K-Esports verticals.Provenance & Compliance - Data Vault® + Web 3.0 Immutable MetadataEnterprise data management and immutable provenance framework for K-Entertainment IP registrations, royalty flow traceability, and institutional-grade KYC/AML compliance aligned with Demora Chain's DMR settlement requirements.Global Digital Infrastructure Platform - Three-Layer ArchitectureThe DVLT partnership operates across the three-layer JP3E platform architecture - with K-Entertainment as the lead vertical:Platform LayerRole & DVLT Integration PointK2Global (Layer 3 - Application)Asset origination layer: 500+ Korean SMBs across 8 K-Wave sectors. K-Entertainment leads - K-Pop concert IP, K-Drama rights, K-Beauty brands, K-Food franchises. K2Global identifies the real-world and IP assets that DVLT's DataScore® and IDE Digital Twin will score, value, and credentialize for tokenization on Demora Chain.JP3E Holdings (Structure & Access)Institutional governance and capital structure layer. Structures regulatory compliance (Clean Wall separation), OTC → NASDAQ pathway, and sovereign capital access. DVLT's KYC/AML-compliant Web3 data management integrates at this governance layer.Demora Foundation (Layer 1 - Tokenize & Liquidate)Converts illiquid K-Entertainment and K-Wave infrastructure assets into tradable DMR-denominated RWA and GMMT-powered VWA instruments via Demora Chain's dual OP Stack Layer 2. DVLT's HPC-powered tokenization platform and immutable metadata framework are the core technology input at this layer - enabling LP waterfall yield + DMR token upside.K-Wave Cities Deployment - DVLT Integration by SectorThe Technology Integration Agreement positions Datavault AI as the enterprise data intelligence and tokenization technology partner across all eight K-Wave growth sectors in three US Innovation Cities - with K-Entertainment as the flagship commercial vertical:K-Wave SectorDVLT Platform ApplicationEntertainment - K-Pop, Drama IP, Digital Content & MediaFLAGSHIP VERTICAL - IDE Digital Twin & NIL credentialing for K-Pop artist IP, K-Drama content rights, and digital royalty tokenization as VWA on GMMT; DataScore® for AI-based content asset valuation and live event revenue forecasting; DMR-LIVE protocol integration for K-Pop concert receivables tokenization as RWA on DMRFood & Beverage - K-Food Franchise, Cuisine & ExportDataValue® for franchise system and supply chain asset scoring; J1Manna DMR RWA settlement for cross-border distribution contracts through Innovation City hubsBeauty & Cosmetics - K-Beauty Brands, Skincare & BiotechDVLT healthcare HPC licensing applied to K-Beauty O-Min, biotech supply chains; IDE Digital Twin for K-Longevity (NovocellBio NK cell) clinical supply RWA tokenizationTechnology / AI - IoT, Robotics & BlockchainDataScore® AI agents for KORECEN biometric patent (13 KIPO finger-vein) valuation as RWA; DVLT Web 3.0 enterprise data management for IoT/robotics SMB IP assetsManufacturing - Advanced Materials, EV Components & BatteriesDVLT immutable metadata for critical minerals provenance; IDE Digital Twin for K-Defense, dual-use hardware supply chain traceability on DMRHealthcare / Bio - Pharmaceuticals, Medical Devices & TelehealthDVLT healthcare HPC licensing and DataValue® for NovocellBio NK cell manufacturing capacity and clinical supply agreement tokenization as K-Longevity RWA on DMRFashion - Contemporary Design & Textile InnovationIDE NIL credentialing for brand and design IP; DataScore® for O-Min fashion IP asset valuation as VWA on GMMT; cross-border distribution RWA on DMREducation / EdTech - E-Learning Platforms & Global CertificationDVLT Web 3.0 data management for SaaS-model EdTech platform data assets; DataScore® for certification IP valuation feeding Demora flywheel programmable yield via DMRStatements"Datavault AI was built for exactly this moment - when AI-powered data intelligence meets institutional blockchain infrastructure at a global scale. The K2Global Innovation K-Wave platform, with K-Entertainment as its flagship vertical, represents one of the most compelling real-world asset mandates in the market today: 200M+ Hallyu fans, $14B+ in K-Pop revenue, 500+ Korean SMBs, three US Innovation Cities, and a two-token blockchain architecture built for institutional settlement. Our Data Vault®, DataValue®, DataScore®, and Digital Twin platforms are the intelligence layer that transforms K-Entertainment IP - from K-Pop concert revenues and K-Drama royalties to K-Beauty brands and K-Food franchises - from illiquid cultural assets into scalable, liquid digital financial products. We are proud to be the technology partner of choice for the JP3E platform."- Nathaniel Bradley, CEO, Datavault AI Inc. (NASDAQ: DVLT)"The Datavault AI partnership is a defining moment for the Global Digital Infrastructure Platform - and specifically for DMR-LIVE, our K-Entertainment RWA tokenization protocol. K-Entertainment is not merely one of eight K-Wave sectors; it is the cultural demand engine that drives all of them. With 200M+ Hallyu fans, $40B+ in annual K-Wave economic impact, and a $3B+ tokenizable K-Entertainment pipeline, DVLT's AI-powered data valuation, Digital Twin technology, and enterprise tokenization stack provide precisely the intelligence infrastructure required to convert Korean cultural IP into institutional-grade, on-chain financial products at global scale. Together, we are building the operating system for K-Wave infrastructure finance."- John K. Park, Chairman & CEO, Demora Foundation / JP3E Holdings Inc.About Datavault AI Inc. (NASDAQ: DVLT)Datavault AI Inc. (NASDAQ:DVLT) is an AI-driven data monetization, RWA tokenization, and Web 3.0 infrastructure company headquartered at One Commerce Square, 2005 Market Street, Suite 2400, Philadelphia, PA 19103. DVLT provides enterprise-grade platforms including Information Data Exchange® (Digital Twin / NIL credentialing), Data Vault®, DataValue®, and DataScore® AI agents, and HPC-powered data valuation and secure monetization infrastructure spanning fintech, healthcare, real estate, and sports & entertainment verticals - including the full K-Entertainment sector. CEO: Nathaniel Bradley. Website: www.datavaultsite.comAbout Demora FoundationDemora Foundation is the institutional governance entity of Demora Chain - a dual OP Stack Layer 2 on Ethereum (target: 560,000+ TPS, USD1 gas model) designed for stablecoin finance, RWA tokenization, and VWA (Virtual Wealth Asset) creation at institutional scale. Demora Foundation governs the DMR-LIVE K-Entertainment RWA tokenization protocol as the flagship product of its K2Global Innovation K-Wave Cities deployment. Demora Foundation is incorporated in Delaware and governed under JP3E Holdings Inc. Website: demora.foundationMedia Contacts:John K. Park, Chairman & CEO - JP3E Holdings Inc. / Demora FoundationJohn.park@jp3e.com | www.jp3e.com | demora.foundationAlan Wallace, Head of Public Relations - Datavault AI / marketing@dvlt.aiInvestor ContactEdward Barger, VP, Investor Relations - Datavault AI, ir@dvlt.ai - ebarger@dvlt.aiSOURCE: Datavault AI Inc Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com